The company said revenue for Q2 2024 (ended June 30, 3 months) was $692 million, compared with $709 million a year earlier, up (2) on a reported basis and (1) organically.

1. 01

   The company said revenue for Q2 2024 (ended June 30, 3 months) was $692 million, compared with $709 million a year earlier, up (2) on a reported basis and (1) organically.

2. 02

   The company said GAAP earnings per share for Q2 were $0.45 ($0.28 a year earlier), and adjusted earnings per share from continuing operations were $1.22 ($1.21 a year earlier). GAAP operating income from continuing operations was $86 million.

3. 03

   The company said Life Sciences revenue for Q2 was $314 million ($336 million a year earlier, a reported decrease of 7%), and Diagnostics revenue was $378 million ($373 million a year earlier, a reported increase of 1%).

4. 04

   The company said it updated its full-year 2024 revenue outlook to $2.77 to $2.79 billion, reflecting recent changes in foreign exchange rates and assuming 2% organic revenue growth, and raised its adjusted EPS outlook to $4.70 to $4.80.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.